286 related articles for article (PubMed ID: 34339036)
21. Lung cancer stem cells and implications for future therapeutics.
Wang J; Li ZH; White J; Zhang LB
Cell Biochem Biophys; 2014 Jul; 69(3):389-98. PubMed ID: 24549856
[TBL] [Abstract][Full Text] [Related]
22. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract][Full Text] [Related]
23. Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment.
Islam F; Gopalan V; Smith RA; Lam AK
Exp Cell Res; 2015 Jul; 335(1):135-47. PubMed ID: 25967525
[TBL] [Abstract][Full Text] [Related]
24. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
26. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
27. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-β pathway.
Wen H; Qian M; He J; Li M; Yu Q; Leng Z
PLoS One; 2020; 15(3):e0230230. PubMed ID: 32214328
[TBL] [Abstract][Full Text] [Related]
29. Truncated Bid Overexpression Induced by Recombinant Adenovirus Cre/LoxP System Suppresses the Tumorigenic Potential of CD133
Long Q; Zhu W; Zhou J; Wu J; Lu W; Zheng C; Zhou D; Yu L; Yang R
Oncol Res; 2017 Apr; 25(4):595-603. PubMed ID: 27760587
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
Yang W; Kim D; Kim DK; Choi KU; Suh DS; Kim JH
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064635
[TBL] [Abstract][Full Text] [Related]
31. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
[TBL] [Abstract][Full Text] [Related]
32. Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines.
Pajuelo-Lozano N; Alcalá S; Sainz B; Perona R; Sanchez-Perez I
Theranostics; 2020; 10(21):9601-9618. PubMed ID: 32863948
[No Abstract] [Full Text] [Related]
33. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
34. Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.
Lee H; Kim JW; Choi DK; Yu JH; Kim JH; Lee DS; Min SH
Biochem Biophys Res Commun; 2020 May; 526(1):158-164. PubMed ID: 32201081
[TBL] [Abstract][Full Text] [Related]
35. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
36. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.
Zakaria N; Yusoff NM; Zakaria Z; Lim MN; Baharuddin PJ; Fakiruddin KS; Yahaya B
BMC Cancer; 2015 Feb; 15():84. PubMed ID: 25881239
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
38. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
39. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
40. Cancer stem cells: problems for therapy?
Alison MR; Lim SM; Nicholson LJ
J Pathol; 2011 Jan; 223(2):147-61. PubMed ID: 21125672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
